RxDoctor Payments Data

Masood Ahmed, MD

Pulmonary Disease · Savannah, GANPI 1255489019

Payments from drug & device makers

$4,586in general payments, 2019–2025

Across 251 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Mylan Specialty L.p.$357
  • Sanofi$243
  • Actelion Pharmaceuticals US, Inc.$242
  • Regeneron Healthcare Solutions, Inc.$200
  • AstraZeneca$191
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,53999%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,586 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$282,539
Medicare patients
502
Services billed
2,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter502$421,834
OfevNintedanib Esylate13$168,955
OzempicSemaglutide55$99,118
EliquisApixaban66$62,570
Dupixent PenDupilumab15$59,838
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$45,691
JanuviaSitagliptin Phosphate18$28,110
MounjaroTirzepatide26$26,657
Breo ElliptaFluticasone/Vilanterol38$26,073
JanumetSitagliptin Phos/Metformin Hcl21$23,727
TrulicityDulaglutide18$22,489
XareltoRivaroxaban25$20,201
FarxigaDapagliflozin Propanediol11$19,113
Janumet XrSitagliptin Phos/Metformin Hcl24$17,562
SymbicortBudesonide/Formoterol Fumarate29$14,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,035$458,646553 claims
Boehringer IngelheimOfev, Stiolto Respimat$172$176,04526 claims
Novo NordiskOzempic$48$99,11855 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$191$79,75287 claims
MerckJanuvia, Janumet, Janumet Xr$65$69,39963 claims
PfizerEliquis$80$62,57066 claims
Johnson & JohnsonXarelto$118$20,20125 claims
AbbVieSynthroid$88$2,12025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →